Cylinder, a leading virtual digestive health provider, has announced a partnership with Teladoc Health to broaden access to high-quality gastrointestinal care for health plan and employer members. With digestive health issues impacting up to 70 million Americans and costing $136 billion annually, this collaboration allows Teladoc’s customers to seamlessly offer Cylinder’s personalized, evidence-based GI care through Teladoc’s Prism platform. Cylinder’s services include access to gastroenterologists, dietitians, and health coaches, delivering tailored care for all acuity levels.
Author: Abhay Panchal
A new Health Affairs study highlights a growing problem for healthcare consumers: higher physician turnover rates in private equity (PE)-acquired practices. Analyzing 200 ophthalmology practices bought by PE firms between 2014 and 2021, researchers found that physician turnover jumped from 4.9% before acquisition to 22.2% afterward — a staggering 17.3 percentage point increase. In contrast, similar non-PE-acquired practices saw turnover grow only slightly, from 7.7% to 8.8%.
In the latest episode of Spill, Medtronic Chairman and CEO Geoff Martha takes us on a journey through the next 100 years of health technology. Whether you’re a tech enthusiast or someone interested in the future of AI and robotics, this episode is packed with insights on the latest innovations transforming the industry.
A new study published in JAMA Network Open found that using an Automatic Quality Control System (AQCS) during routine colonoscopy significantly increased adenoma detection rates (ADR), particularly among low- and medium-level detectors. In this multicenter randomized trial in China involving over 1,200 patients, the AQCS-assisted group achieved an ADR of 32.7% compared to 22.6% in the standard colonoscopy group. AQCS also improved detection of nonadvanced adenomas and flat or sessile lesions, with benefits seen across both academic and non-academic centers. Although the AQCS group had slightly longer withdrawal times, no serious adverse events occurred. Researchers conclude that AQCS can meaningfully…
Australian startup Biomebank, known for its world-first regulatory approval of fecal microbiota transplants, is raising $4 million to develop a lab-grown gut therapy aimed at the U.S. market. Founder Sam Costello shared that initial feedback from the FDA on their cultured therapy has been positive, with clear manufacturing parameters established. However, Biomebank’s U.S. expansion faces regulatory uncertainty as potential reforms under Elon Musk’s Department of Government Efficiency (DOGE) and shifting political dynamics, including RFK Jr.’s influence, create an unclear future for FDA oversight.
QIAGEN has received FDA clearance for its QIAstat-Dx Gastrointestinal Panel 2 Mini B, expanding its U.S. syndromic testing portfolio for gastrointestinal infections. The panel rapidly detects five key bacterial pathogens—Campylobacter, Salmonella, STEC, Shigella, and Yersinia enterocolitica—in about one hour, supporting fast outpatient diagnostics. This is QIAGEN’s second FDA-cleared QIAstat-Dx panel in 2025 and complements their existing bacterial and viral GI panels, offering laboratories targeted, flexible solutions for diverse clinical settings.
A new study examining U.S. physician mortality reveals a surprising trend—unlike the general population where women live significantly longer than men, women doctors do not share this mortality advantage. While women in other high-income, high-education professions like law and engineering experience lower death rates than their male counterparts, female physicians die at rates similar to male physicians. The reasons remain unclear but may include chronic workplace stress, gender bias, slower promotions, pay gaps, and the double burden of professional and home responsibilities.
The Scope Forward Show is Back – Kicking Off with Dr. Michael Dragutsky The wait is over—The Scope Forward Show returns with Season 5, and we’re starting with someone who has been at the center of GI’s transformation: Dr. Michael Dragutsky, Chairman of One GI. A lot has changed since we last spoke. Private equity in GI has evolved. Consolidation is accelerating. AI is no longer a distant concept—it’s happening now. Where does this leave private practice? What’s next after the first, second, and third bites of private equity? And for those who feel like they’re losing control of their practice, is there still…
Summerville Medical Center recently marked a major milestone in its minimally invasive robotic surgery program, performing the first procedure using its new state-of-the-art robotic surgical system.
Teladoc Health (NYSE: TDOC) has announced a pharmacy integration agreement with Eli Lilly’s LillyDirect pharmacy partner, Gifthealth, aimed at streamlining access to Zepbound® (tirzepatide) for Teladoc Health members enrolled in its Comprehensive Weight Care Program.This collaboration ensures that eligible patients without insurance coverage for GLP-1s can receive affordable, safe, and effective weight-loss medication. Through LillyDirect, prescribed Zepbound® will be delivered directly to patients’ homes in single-use vials.